A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Human Molecular Genetics

• Publication date

  2017-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/hmg/ddx166PMID 28460014PMCID PMC5886194
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis.

  2017cited by this paper
• Commonality amid diversity: Multi-study proteomic identification of conserved disease mechanisms in spinal muscular atrophy.

  2016cited by this paper
• The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype.

  2016cited by this paper
• Quantitative proteomics identifies myoferlin as a novel regulator of A Disintegrin and Metalloproteinase 12 in HeLa cells.

  2016cited by this paper
• Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity in the ∆7 SMA Mouse

  2015cited by this paper
• SAM68 is a physiological regulator of SMN2 splicing in spinal muscular atrophy

  2015cited by this paper
• Targeting SR Proteins Improves SMN Expression in Spinal Muscular Atrophy Cells

  2014influential reference
• Dysregulation of ubiquitin homeostasis and beta-catenin signaling promote spinal muscular atrophy

  2014cited by this paper
• Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy.

  2014cited by this paper
• PTEN Depletion Decreases Disease Severity and Modestly Prolongs Survival in a Mouse Model of Spinal Muscular Atrophy

  2014cited by this paper
• Regulation of telomerase alternative splicing: a target for chemotherapy.

  2013cited by this paper
• Mechanisms coordinating ELAV/Hu mRNA regulons.

  2013cited by this paper
• Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality.

  2013cited by this paper
• Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy

  2012cited by this paper
• Mechanisms of activation and repression by the alternative splicing factors RBFOX1/2.

  2012cited by this paper
• The Survival of Motor Neuron (SMN) Protein Interacts with the mRNA-Binding Protein HuD and Regulates Localization of Poly(A) mRNA in Primary Motor Neuron Axons

  2011cited by this paper
• Hu proteins regulate alternative splicing by inducing localized histone hyperacetylation in an RNA-dependent manner

  2011cited by this paper
• Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR.

  2011cited by this paper
• Interaction of survival of motor neuron (SMN) and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficits

  2011cited by this paper
• HuD interacts with survival motor neuron protein and can rescue spinal muscular atrophy-like neuronal defects.

  2011cited by this paper
• Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model.

  2010cited by this paper
• Promotion of exon 6 inclusion in HuD pre-mRNA by Hu protein family members

  2010cited by this paper
• The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor

  2010cited by this paper
• A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophy

  2010cited by this paper
• Cooperative-Binding and Splicing-Repressive Properties of hnRNP A1

  2009cited by this paper
• A positive modifier of spinal muscular atrophy in the SMN2 gene.

  2009influential reference
• p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR.

  2009cited by this paper
• UNAFold: software for nucleic acid folding and hybridization.

  2008cited by this paper
• Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice.

  2008cited by this paper
• Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy

  2008cited by this paper
• Diverse molecular functions of Hu proteins

  2008influential reference
• Regulation of SMN Protein Stability

  2008cited by this paper
• Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC

  2007cited by this paper
• Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.

  2007cited by this paper
• Specific Protein Domains Mediate Cooperative Assembly of HuR Oligomers on AU-rich mRNA-destabilizing Sequences*

  2007cited by this paper
• Spinal Muscular Atrophy: Clinical Classification and Disease Heterogeneity

  2007cited by this paper
• Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon

  2007cited by this paper
• Regulation of Neuron-Specific Alternative Splicing of Neurofibromatosis Type 1 Pre-mRNA

  2007cited by this paper
• An intronic element contributes to splicing repression in spinal muscular atrophy

  2007cited by this paper
• The role of histone acetylation in SMN gene expression.

  2005cited by this paper
• Modulation of SMN nuclear foci and cytoplasmic localization by its C-terminus

  2004cited by this paper
• Active Transport of the Survival Motor Neuron Protein and the Role of Exon-7 in Cytoplasmic Localization

  2003cited by this paper
• Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1

  2003cited by this paper
• Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2

  2002cited by this paper
• Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.

  2002cited by this paper
• Essential Role for the SMN Complex in the Specificity of snRNP Assembly

  2002cited by this paper
• A multiprotein complex mediates the ATP-dependent assembly of spliceosomal U snRNPs

  2001cited by this paper
• The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy.

  2000cited by this paper
• A mouse model for spinal muscular atrophy

  2000cited by this paper
• Mouse model of spinal muscular atrophy.

  2000cited by this paper
• A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.

  1999cited by this paper
• A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.

  1999cited by this paper
• hnRNP A/B proteins are required for inhibition of HIV‐1 pre‐mRNA splicing

  1999cited by this paper
• Correlation of SMNt and SMNc gene copy number with age of onset and survival in spinal muscular atrophy

  1998cited by this paper
• Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number.

  1998cited by this paper
• The three-dimensional structures of two complexes between recombinant MS2 capsids and RNA operator fragments reveal sequence-specific protein-RNA interactions.

  1997cited by this paper
• Correlation between severity and SMN protein level in spinal muscular atrophy

  1997cited by this paper
• Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number.

  1997cited by this paper
• Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype.

  1997cited by this paper
• The neurobiology of childhood spinal muscular atrophy.

  1996cited by this paper
• Identification and characterization of a spinal muscular atrophy-determining gene

  1995cited by this paper

• Non-Cell-Autonomous Mechanisms and Systemic Interactions in Spinal Muscular Atrophy.

  2026cites this paper
• SMN deficiency inhibits endochondral ossification via promoting TRAF6-induced ubiquitination degradation of YBX1 in spinal muscular atrophy

  2025cites this paper
• Updates of spinal muscular atrophy in advanced therapies.

  2025cites this paper
• Loss of SMN Impairs Osteoblast–Osteoclast Coupling via IGF1–Akt–OPG Axis in Spinal Muscular Atrophy

  2025cites this paper
• Clinically Discordant Siblings with Spinal Muscular Atrophy: Insights from Patient-Specific iPSC-Derived Motor Neurons and Literature Review

  2025cites this paper
• Single Nucleotide SMN1 Variants in a Cohort of Individuals With Spinal Muscular Atrophy

  2025cites this paper
• Epigenetic regulation in spinal muscular atrophy: emerging areas and future directions

  2025cites this paper
• Comprehensive analysis across SMN2 excludes DNA methylation as an epigenetic biomarker for spinal muscular atrophy

  2025cites this paper
• Frataxin: from the sequence to the biological role

  2025cites this paper
• Correlation Between Neuronal Apoptosis Inhibitory Protein (NAIP), SMN2, and SMA Phenotypes: A Tertiary Care Centre Experience From India

  2025cites this paper
• Whole-transcriptome sequencing in neural and non-neural tissues of a mouse model identifies miR-34a as a key regulator in SMA pathogenesis

  2025cites this paper
• [Research progress on phenotypic modifier genes in spinal muscular atrophy].

  2025cites this paper
• Quantitative and structural features of the SMN1 and SMN2 genes in patients with spinal muscular atrophy 5q

  2025cites this paper
• Outcomes of a Pilot Newborn Screening Program for Spinal Muscular Atrophy in the Valencian Community

  2025cites this paper
• Unraveling the genetic mysteries of spinal muscular atrophy in Chinese families

  2025cites this paper
• Challenges and opportunities in spinal muscular atrophy therapeutics.

  2024cites this paper
• Framework and overview of the Pediatric Spinal Muscular Atrophy Registry Program of Iran

  2024cites this paper
• The Relevance of Spinal Muscular Atrophy Biomarkers in the Treatment Era

  2024cites this paper
• In Search of Spinal Muscular Atrophy Disease Modifiers

  2024cites this paper
• Onasemnogene‐abeparvovec administration to premature infants with spinal muscular atrophy

  2024cites this paper
• Clinical decision making around commercial use of gene and genetic therapies for spinal muscular atrophy

  2024cites this paper
• Complex SMN Hybrids Detected in a Cohort of 31 Patients With Spinal Muscular Atrophy

  2024cites this paper
• Long-read sequencing identifies copy-specific markers of SMN gene conversion in spinal muscular atrophy

  2024cites this paper
• Management and Therapeutic Strategies for Spinal Muscular Atrophy

  2024cites this paper
• Variants located in intron 6 of SMN1 lead to misdiagnosis in genetic detection and screening for SMA

  2024cites this paper
• Specificity, synergy, and mechanisms of splice-modifying drugs

  2024cites this paper
• 5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2

  2024cites this paper
• Spinal muscular atrophy: Molecular mechanism of pathogenesis, diagnosis, therapeutics, and clinical trials in the Indian context

  2024cites this paper
• Factors modifying the course of spinal muscular atrophy 5q

  2024cites this paper
• Spinal Muscular Atrophy: An Overview

  2023cites this paper
• A high-fidelity long-read sequencing-based approach enables accurate and effective genetic diagnosis of spinal muscular atrophy.

  2023cites this paper
• 270th ENMC International Workshop: Consensus for SMN2 genetic analysis in SMA patients 10-12 March, 2023, Hoofddorp, the Netherlands.

  2023cites this paper
• Development of 2′-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells

  2023cites this paper
• Specificity, synergy, and mechanisms of splice-modifying drugs

  2023cites this paper
• Identification of two short peptide motifs from serine/arginine-rich protein ribonucleic acid recognition motif-1 domain acting as splicing regulators

  2023cites this paper
• Newborn screening for spinal muscular atrophy - what have we learned?

  2023cites this paper
• Childhood spinal muscular atrophy.

  2023cites this paper
• HnRNPR strongly represses splicing of a critical exon associated with spinal muscular atrophy through binding to an exonic AU-rich element

  2023cites this paper
• Spinal muscular atrophy

  2022cites this paper
• Rescue of mis-splicing of a common SLC26A4 mutant associated with sensorineural hearing loss by antisense oligonucleotides

  2022cites this paper
• NOVA1 promotes SMN2 exon 7 splicing by binding the UCAC motif and increases SMN protein expression

  2022cites this paper
• Current Trends in the Diagnosis, Screening and Treatment of Spinal Muscular Atrophy

  2022cites this paper
• Single-cell RNA sequencing reveals dysregulation of spinal cord cell types in a severe spinal muscular atrophy mouse model

  2022cites this paper
• Deep Molecular Characterization of Milder Spinal Muscular Atrophy Patients Carrying the c.859G>C Variant in SMN2

  2022cites this paper
• History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy

  2022cites this paper
• Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies

  2022cites this paper
• Recommendations for Interpreting and Reporting Silent Carrier and Disease-Modifying Variants in SMA Testing Workflows

  2022cites this paper
• Position-dependent effects of hnRNP A1/A2 in SMN1/2 exon7 splicing.

  2022cites this paper
• A splicing silencer in SMN2 intron 6 is critical in spinal muscular atrophy.

  2022cites this paper
• Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis

  2022cites this paper
• MLPA analysis for molecular diagnosis of spinal muscular atrophy and correlation of 5q13.2 genes with disease phenotype in Egyptian patients

  2022cites this paper
• Structure and function analysis of Sam68 and hnRNP A1 synergy in the exclusion of exon 7 from SMN2 transcripts

  2022cites this paper
• splice sites by noncanonical base-pairing to U1 snRNA involving

  2022cites this paper
• Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance

  2021cites this paper
• Targeted editing of intronic-splicing silencer enhancement of SMN2 Exon 7 inclusion by CRISPR/Case 9

  2021cites this paper
• NOVA1 Promotes SMN2 Exon 7 Splicing via Binding the UCAC Motif and Increases SMN Protein Expression

  2021cites this paper
• Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy

  2021cites this paper
• Detection of SMN1 to SMN2 gene conversion events and partial SMN1 gene deletions using array digital PCR

  2021cites this paper
• SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples

  2021cites this paper
• What Genetics Has Told Us and How It Can Inform Future Experiments for Spinal Muscular Atrophy, a Perspective

  2021cites this paper
• The Importance of Digging into the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy

  2021influential citation
• Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice.

  2021cites this paper
• Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development

  2021cites this paper
• Advances in the therapy of Spinal Muscular Atrophy.

  2021cites this paper
• Multi-site Evaluation and Validation of a Sensitive Diagnostic and Screening System for Spinal Muscular Atrophy that Reports SMN1 and SMN2 Copy Number, along with Disease Modifier and Gene Duplication Variants.

  2021cites this paper
• Observation of the natural course of type 3 spinal muscular atrophy: data from the polish registry of spinal muscular atrophy

  2021cites this paper
• Beyond copy number: A new, rapid, and versatile method for sequencing the entire SMN2 gene in SMA patients

  2021cites this paper
• Antisense technology: A review

  2021cites this paper
• In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy

  2021cites this paper
• RNA-Targeted Therapies and High-Throughput Screening Methods

  2020cites this paper
• Molecular diagnosis and genetic counseling for spinal muscular atrophy (SMA).

  2020cites this paper
• U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing

  2020cites this paper
• Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy

  2020cites this paper
• Development and validation of a 4-color multiplexing spinal muscular atrophy (SMA) genotyping assay on a novel integrated digital PCR instrument

  2020cites this paper
• Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy

  2020influential citation
• Incorporating Spinal Muscular Atrophy Analysis by Next-Generation Sequencing into a Comprehensive Multigene Panel for Neuromuscular Disorders

  2020cites this paper
• Spinal muscular atrophy in Venezuela: quantitative analysis of SMN1 and SMN2 genes

  2020cites this paper
• The GENDULF algorithm: mining transcriptomics to uncover modifier genes for monogenic diseases

  2020cites this paper
• Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model

  2020cites this paper
• Understanding and targeting the disease‐related RNA binding protein human antigen R (HuR)

  2020cites this paper
• 244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofdorp, The Netherlands.

  2019cites this paper
• Modulation of PDCD1 exon 3 splicing

  2019cites this paper
• Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy

  2019cites this paper
• High-throughput screening reveals novel mutations in spinal muscular atrophy patients

  2019cites this paper
• Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors

  2019cites this paper
• [Antisense oligonucleotides in SMA: lessons learned and literature data].

  2019cites this paper
• SMN deficiency causes pain hypersensitivity in a mild SMA mouse model through enhancing excitability of nociceptive dorsal root ganglion neurons

  2019cites this paper
• Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype

  2019cites this paper
• Spinal muscular atrophy within Amish and Mennonite populations: Ancestral haplotypes and natural history

  2018cites this paper
• Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes.

  2018cites this paper
• Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible Disease-modifying Candidates

  2018cites this paper
• A severe mouse model of spinal muscular atrophy develops early systemic inflammation

  2018cites this paper
• Novel challenges in spinal muscular atrophy – How to screen and whom to treat?

  2018cites this paper
• Downregulation of Survivin contributes to cell-cycle arrest during postnatal cardiac development in a severe spinal muscular atrophy mouse model

  2018cites this paper
• Motor neuron biology and disease: A current perspective on infantile-onset spinal muscular atrophy.

  2018cites this paper
• Therapeutic advances in 5q-linked spinal muscular atrophy

  2017cites this paper